GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Immune globulin subcutaneous 20% (XEMBIFY)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

XEMBIFY

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - XEMBIFY

Product / population
XEMBIFY subcutaneous immune globulin; product-specific renal precautions, not an IV infusion schedule.
Renal measure
Qualitative renal risk; BUN/creatinine and urine output.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

The product contains no sucrose, but that does not eliminate renal risk. Avoid volume depletion, assess renal function before the first infusion and periodically, and monitor urine output in susceptible patients. Consider lower, more frequent doses for patients at risk of renal dysfunction and consider discontinuation if kidney function deteriorates. No fixed renal percentage reduction is provided in this selected source.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/xembify-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

GlobalRPh RX List

GlobalRPh RX List - XEMBIFY

Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.

XEMBIFY 20% subcutaneous immune globulin; not IV administration.

Renal method: Renal-risk assessment and BUN/creatinine monitoring; no numerical renal dose bands.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - XEMBIFY

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

XEMBIFY subcutaneous immune globulin; product-specific renal precautions, not an IV infusion schedule.

Renal method: Qualitative renal risk; BUN/creatinine and urine output.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - XEMBIFYGlobalRPh RX List - XEMBIFY
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/xembify-drug/

Exact product and population

XEMBIFY 20% subcutaneous immune globulin; not IV administration.

RDM35-SCOPE-immune-globulin-xembify-sc · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - XEMBIFY

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · XEMBIFY 20% subcutaneous immune globulin; not IV administration.

Renal method: Renal-risk assessment and BUN/creatinine monitoring; no numerical renal dose bands.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The sucrose-free formulation does not eliminate the immune-globulin renal-injury warning. Correct volume depletion before treatment. In patients at renal risk, monitor kidney function and consider smaller, more frequent doses. Assess BUN/serum creatinine before the first infusion and periodically thereafter; follow urine output. Consider discontinuation if kidney function deteriorates. The source provides no CrCl-to-dose table here. This is a subcutaneous product, not an IV immune-globulin infusion schedule.

RDM35-rxlist-immune-globulin-xembify-sc-872f0b45a4-C1 · Source locator: Renal impairment; dosage; warnings; pharmacokinetics, as identified in the selected retrieval.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/xembify-drug/
Retrieved
2026-09-07
Renal-function method
Renal-risk assessment and BUN/creatinine monitoring; no numerical renal dose bands.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
df9dbe331c6619028df085c32f8d77e456d96c59ca828d7036372877d8618c31
Rxlist

GlobalRPh RX List - XEMBIFY

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · XEMBIFY subcutaneous immune globulin; product-specific renal precautions, not an IV infusion schedule.

Renal method: Qualitative renal risk; BUN/creatinine and urine output.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The product contains no sucrose, but that does not eliminate renal risk. Avoid volume depletion, assess renal function before the first infusion and periodically, and monitor urine output in susceptible patients. Consider lower, more frequent doses for patients at risk of renal dysfunction and consider discontinuation if kidney function deteriorates. No fixed renal percentage reduction is provided in this selected source.

RDM43-rxlist-immune-globulin-xembify-sc-872f0b45a4-C1 · Source locator: Selected Dosage / Renal Impairment / Warnings sections; see source-specific qualifications in this summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/xembify-drug/
Retrieved
2026-09-07
Renal-function method
Qualitative renal risk; BUN/creatinine and urine output.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
1020ea3a6c437339b7d9a078cf56493cacd35674645dfe4ecc299254de872e1f

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/xembify-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
883114a4c490da46c2ba6a6219b28b29e82dc70079ecb55f8d3194552fdcabea
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report